| Document |
Document Title |
|
WO/1999/003859A1 |
A compound of formula (I) wherein n is 0 or 1; m is 0 or 1; p is 0 or 1; X is oxygen or sulfur; Y is CH, N or NO; W is oxygen, H¿2? or F¿2?; A is N or C(R?2¿); G is N or C(R?3¿); D is N or C(R?4¿); with the proviso that no more than...
|
|
WO/1998/058931A1 |
A process for producing $g(b)-lactam derivatives, characterized by treating a $g(b)-lactam derivative having a protected carboxyl group and represented by the general formula (1): A-COO-X (wherein A is a $g(b)-lactam derivative residue; ...
|
|
WO/1998/048037A1 |
The invention relates to a method for controlling the solubility of a $g(b)-lactam nucleus having general formula (I) wherein R�0? is hydrogen or C�1-3? alkoxy; Y is CH�2?, oxygen, sulfur, or an oxidized form of sulfur; and Z is (a...
|
|
WO/1998/046566A1 |
The present invention relates to novel $g(b)-lactam compounds, their pharmacologically acceptable salts and prodrugs, which exhibit antibiotic activity against a broad spectrum of organisms, especially bacteria which are resistant to con...
|
|
WO/1998/039336A1 |
A process for producing exo-methylenepenam compounds of general formula (2), wherein R?1� represents a hydrogen atom, an amino group or a protected amino group; R?2� represents a hydrogen atom, a halogen atom or the like; and R?3� ...
|
|
WO/1998/032766A1 |
The present invention provides substituted amino bicyclic-$g(b)-lactam penam derivatives and substituted amino bicyclic-$g(b)-lactam cepham derivatives and their diastereoisomers of general formula (I) as well as compositions containing ...
|
|
WO/1998/032718A1 |
The properties of biologically active compounds, for example drugs and agrochemicals, which contain in their molecular structure one or more functional groups selected from alcohol, ether, phenyl, amino, amido, thiol, carboxylic acid and...
|
|
WO/1998/024775A1 |
The invention relates to a method for producing metal complex carboxylic acid amides characterized in that a metal complex carboxylic acid mixture consisting of metal complex carboxylic acid and at least one solubilizing substance is pre...
|
|
WO/1998/004732A1 |
Disclosed is a process for the synthesis of $g(b)-lactam antibacterials using soluble side chain esters in the presence of enzyme acylase. Also disclosed are novel esters useful as reactants in said process.
|
|
WO/1998/000429A1 |
The invention provides a process for the preparation of compounds of formula (I) wherein R?1�, R?2�, R?3�, R?4� and R?5� are as defined in the specification; and wherein any functional groups are optionally protected; and salts...
|
|
WO/1997/049670A1 |
The invention concerns new catechol derivatives of the general formula (I), in which azomethine-carboxylic acid rests, azobenzene-carboxylic acid rests, benzhydrazon rests, aminobenzoic acid rests and amino acid rests or dipeptides, pyrr...
|
|
WO/1997/047301A1 |
A new crystalline form of potassium clavulanate is disclosed. Also disclosed are a process for producing the new crystalline form of potassium clavulanate, pharmaceutical compositions containing it and methods of treating bacterial infec...
|
|
WO/1997/042177A1 |
A new process is described for the synthesis of ureide derivatives having formula (I) where the P ring is a saturated or unsaturated nitrogen heterocycle with 5 or 6 members, possibly containing, in addition, one or more hetero-atoms cho...
|
|
WO/1997/035029A1 |
Alternative process to obtain 6-amino-penicillanic acid. The process comprises the substitution of the steps of extraction with organic solvents and isolation and separation as solid material of the intermediary penicillin salt, by a cul...
|
|
WO/1997/031922A1 |
It is described a process for the preparation of 2-halomethyl-penems (in particular 2-chloromethyl-penems) comprising, as intermediate step, the formation of the corresponding 2-haloacetylthio-azetidone.
|
|
WO/1997/030984A1 |
Compounds that possess selectin binding activity are described that have a three-dimensionally stable configuration for sialic acid and fucose, or analogs, derivatives, or mimics of these groups, such that sialic acid and fucose or their...
|
|
WO/1997/031006A1 |
Compounds that possess selection binding activity are described that have a three-dimensionally stable configuration for sialic acid and fucose, or analogs, derivatives, or mimics of these groups, such that sialic acid and fucose or thei...
|
|
WO/1997/017352A1 |
An efficient process for de-esterification has been provided for by application of special tetrahalogenides. By applying this process a new compound, viz. cefesone, and especially the E-isomer thereof, has been prepared.
|
|
WO/1997/015579A1 |
A process for the production of a crystalline salt, e.g. sodium, of amoxicillin, in ethanol as solvent, the use of ethanol as solvent in the crystallization of a salt, e.g. sodium, of amoxicillin and a crystalline salt of amoxicillin con...
|
|
WO/1997/012889A1 |
New solvates of penicillin, in particular amoxycillin glycolate has been provided for together with a simple one-step process to prepare the same.
|
|
WO/1997/009052A1 |
Pharmaceutical prodrug compositions are provided comprising azide derivatives of drugs which are capable of being converted to the drug in vivo. Azide derivatives of drugs having amine, ketone and hydroxy substituents are converted in vi...
|
|
WO/1997/006172A1 |
Novel 3-(substituted)-3-methyl-4-thia-1-azabicyclo[3.2.0]heptane-2
-carboxylate, 4,4-dioxides of formula (I) wherein R2 is OR3 or NR4R5, which are of value for use in combination with 'beta'-lactam antibiotics to increase the effectivene...
|
|
WO/1997/000259A1 |
A novel process for producing penicillin G phenyl esters represented by formula (I), or salts thereof by the reaction between a compound represented by formula (II), or a salt thereof and the compound represented by formula (IV) or a sal...
|
|
WO/1996/040978A1 |
The present invention provides detectable compounds comprising a chemically-transformable first compound covalently linked to an electrochemiluminescent compound. These compounds are useful in processes and kits that monitor the status o...
|
|
WO/1996/040156A1 |
Novel chemotherapeutic agents having utility in treating infectious diseases such as periodontal disease, certain urinary tract infections, infectious urinary tract stones, and bone cancer, are obtained by combining chemically a diphosph...
|
|
WO/1996/040190A1 |
Novel chemotherapeutic agents having utility in treating infectious diseases such as periodontal disease, certain urinary tract infections, infectious urinary tract stones, and bone cancer, are obtained by combining chemically a diphosph...
|
|
WO/1996/038450A1 |
The present invention includes novel (7R)-7-(acylamino)-3-(arylthio)-3-cephem-4-carboxylic acids or their pharmacologically acceptable salts which exhibit antibiotic activity against a wide spectrum of organisms including organisms which...
|
|
WO/1996/038448A1 |
The compounds of formulae A-D, wherein: X is selected from the group consisting of CH2, S, and O; T is selected from the group consisting of CH2 and O; U is selected from the group consisiting of CH2, S, O, and CH(alkyl), where alkyl is ...
|
|
WO/1996/036627A1 |
The present invention relates to the field of combinatorial carbohydrate chemistry and involves the modification of organic molecules and/or the synthesis of large numbers of products comprising carbohydrate and/or glycominetic entities....
|
|
WO/1996/034846A1 |
Compounds of 1,3-propane diol linked structure (I), when for use in therapy, where R1 is an acyl or fatty alcohol group derived from a C12-30 preferably C16-30 fatty acid desirably with two or more cis or trans double bonds, and R2 is hy...
|
|
WO/1996/034855A1 |
Compounds of structure (I), and when for use in therapy: where R1 is an acyl group derived from a C16-30 fatty acid with two or more cis or trans double bonds and particularly an n-6 or n-3 series EFA or conjugated linoleic acid, or colu...
|
|
WO/1996/034858A1 |
Niacin as a compound, per se or for use in therapy, of structure (I), where B is -C(=O)- (nicotinic acid) or -CH2-O- (niacin alcohol), the "link" C which is optional is a diol or hydroxy carboxylic acid or dicarboxylic acid residue, and ...
|
|
WO/1996/030376A1 |
Process for the recovery of ampicillin from a mixture containing ampicillin and 6-aminopenicillic acid (6-APA), in which a mixture of ampicillin and 6-APA, with a pH higher than 7, which apart from any solid ampicillin being present is h...
|
|
WO/1996/028422A1 |
A process for the production of a halogenated 'beta'-lactam compound represented by general formula (2) which comprises replacing the hydroxyl group of a halogenated 'beta'-lactam compound represented by general formula (1) with a haloge...
|
|
WO/1996/025417A1 |
A penem derivative represented by general formula (I), or a pharmacologically acceptable salt thereof, wherein R1 represents optionally substituted alkyl, optionally substituted alkenyl, optionally substituted aralkyl, optionally substit...
|
|
WO/1996/023797A1 |
Process for the recovery of a 'beta'-lactam antibiotic from a mixture containing the ammonium salt of the 'beta'-lactam antibiotic and the ammonium salt of the corresponding 'beta'-lactam core by subjecting the mixture to a physical trea...
|
|
WO/1996/022296A1 |
A back extraction process in which beta-lactam antibiotics or clavulanic acid is extracted from an organic solvent phase into an aqeous medium phase, using a mixing region in which the phases are mixed rapidly under high turbulence and s...
|
|
WO/1996/016067A1 |
A process for the silylation of 6-aminopenicillanic acid or 7-amino-desacetoxy-cephalosporanic acid by silylation in certain carboxylic acid esters and its use in the production of 6-alpha-aminoacyl-penicillins and 7-alpha-aminoacyl-desa...
|
|
WO/1996/004247A1 |
The present invention provides a process for making a compound having a structure according to formula (I) wherein A1, A2 and A3 are independently carbon or nitrogen and R1, R3, R4 and R6 are known quinolone substituents; and wherein one...
|
|
WO/1996/004285A1 |
A 6'beta'-substituted penicillanic acid of formula (XII) or a pharmaceutically acceptable salt or ester thereof, wherein A and B are each hydrogen wherein the carbon atoms to which A and B are attached are linked by a single bond, or A a...
|
|
WO/1996/004286A1 |
The present invention provides processes for making compounds of the structure (Q-L1)-L-(L2-B), wherein (I) Q is a quinolone moiety; (II) B is a lactam moiety; and (III) L, L1, and L2 together comprise a linking moiety; comprising the st...
|
|
WO/1995/034566A1 |
The present invention is related to compounds which inhibit pancreatic cholesterol esterase. The compounds have formula (I), wherein R1 is H or C1-6 alkyl; R2 is H or C1-6 alkyl; R3 is H or C1-6 alkyl; X is CHR6, S or O; R6 is H or C1-6 ...
|
|
WO/1995/029182A1 |
Intermediates in the production of cephalosporins of formula (IA) wherein either 'alpha') Ra denotes hydrogen or a silyl group; Rb denotes a group of formula -ORe, wherein Re denotes hydrogen or alkyl; and Rc and Rd together denote a bon...
|
|
WO/1995/026966A1 |
The present invention includes novel (7R)-7-(acylamino)-3-(arylthio)-3-cephem-4-carboxylic acids or their pharmacologically acceptable salts which exhibit antibiotic activity against a wide spectrum of organisms including organisms which...
|
|
WO/1995/012601A1 |
Crystalline sodium 2'alpha'-methyl-2'beta'-(1,2,3-triazol-1-yl)-methylpenam-3'a
lpha'-carboxylate-1,1-dioxide monohydrate (crystalline tazobactam sodium monohydrate) obtainable by adding to a concentrated aqueous solution of sodium 2'alp...
|
|
WO/1995/000477A1 |
The invention concerns nitrates containing a disulphide group and having for instance formula (I) in which R, R', R1, R1', R2, R2', R3, R3', R4, R4', R5, R5', m, m', n, n', o, o', p, p', q and q' are as defined in claim 1, plus methods o...
|
|
WO/1994/022819A1 |
A process for the preparation of a compound of formula (IVA) which process comprises subjecting a compound of formula (V), where R is an ester-forming group or carboxy-protecting group, and X and Y are hydrogen or halogen provided that a...
|
|
WO/1994/010178A1 |
Compounds of formula (I) in which: R1 is hydrogen or an organic substituent group; R2 is a fused bicyclic heterocyclic ring system of general formula (a) wherein R4 and R5 are independently hydrogen or one or more substituents replacing ...
|
|
WO/1994/006803A1 |
Described are penems derivatives of general formula (I) wherein R1 is chosen in the group consisting of H, C1-C6 alkyl, C1-C6 alkoxy, C3-C7 cycloalkyl, optionally protected C1-C6 hydroxyalkyle; R2 is chosen in the group consisting of car...
|
|
WO/1994/003168A1 |
The use of a 5S penem compound of general formula (I) wherein n is 0 or 1, R2 is hydrogen or a substituent group, R3 is an ester- or amide-forming group, and R1 is hydrogen or an organic group linked via carbon and wherein the group -COR...
|
